Drug intelligence / Profile preview

PAS-011

Development stage: Unknown
Lead developer: Porton Advanced Solutions
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

PAS-011 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Porton Advanced. It is engineered to express a CAR that specifically recognizes the CD19 antigen, a protein found on the surface of most B-cell lineage cells. When these engineered T cells encounter CD19-positive cells, they undergo activation and expansion, leading to the direct lysis of the target B cells. PAS-011 is primarily indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and has received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) in China.

Other names: CD19-CAR-T cell therapyCD-19-CAR-T cell therapyCD 19-CAR-T cell therapy

Beyond the preview

Go deeper on PAS-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAS-011.

Explore the full profile